Affinage

Showing CCR6 — DCR2 is a alias.

CCR6

C-C chemokine receptor-like 2 · UniProt O00421

Length
344 aa
Mass
39.5 kDa
Annotated
2026-06-09
100 papers in source corpus 38 papers cited in narrative 38 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CCR6 is a Gαi-coupled seven-transmembrane chemokine receptor that directs chemotaxis of immune and epithelial cell populations toward its specific ligand CCL20/LARC, governing mucosal and inflammatory tissue homing (PMID:9169459, PMID:15483227). CCL20 binds CCR6 with nanomolar affinity and selectively triggers calcium flux and directed migration; cryo-EM of the CCL20–CCR6–Gαo complex shows the ligand engaging a shallow extracellular pocket that allosterically rearranges a noncanonical toggle switch to open the intracellular G-protein crevice, a non-deep mode of protein-agonist activation (PMID:9169459, PMID:32541785). Downstream of pertussis-toxin-sensitive Gαi, CCR6 inhibits cAMP production and phosphorylates p130Cas, and through Akt/mTOR/STAT3 and AKT/NF-κB/VEGF signaling shapes cell migration, survival, and lineage decisions (PMID:15483227, PMID:29126851, PMID:29097259). CCR6 is required for trafficking of myeloid dendritic cells to the Peyer's-patch subepithelial dome and for mucosal IgA immunity, and for recruitment of Th17 cells, IL-10-producing colon-tropic iTregs, B cells, neutrophils, plasmacytoid DCs, monocytes, and γδ T cells to epithelial and inflamed tissues (PMID:11254677, PMID:11754009, PMID:19050256, PMID:20720211, PMID:21680896, PMID:23959575). Its expression is transcriptionally programmed by RORα/RORγt and PLZF (ZBTB16) in Th17 cells and dynamically tuned by cytokines such as TGF-β, IL-10, IL-4, and IFN-γ (PMID:19050256, PMID:25833398, PMID:11698430). CCR6 signaling also acts beyond leukocyte trafficking: it promotes osteoblast differentiation and survival via PI3K-AKT (PMID:26890063), drives CCL20-dependent tumor growth, angiogenesis, EMT, and Treg-mediated immunosuppression across colorectal, ovarian, gastric, and cutaneous T-cell malignancies (PMID:24866282, PMID:29097259, PMID:35863523, PMID:39133127, PMID:26044596), mediates CatSper-dependent Ca2+ influx and chemotaxis in sperm (PMID:29207656), and associates with TFEB to block autophagic flux in endometriotic stromal cells (PMID:35841069). High-resolution inactive-state structures define two distinct allosteric antagonist pockets, providing a template for small-molecule CCR6 inhibitors (PMID:39217154, PMID:37142443).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1997 High

    Establishing the receptor's ligand identity was the foundational question; pairing CCR6 with CCL20 defined its molecular input and selectivity.

    Evidence Calcium flux, chemotaxis, and SEAP-fusion saturation binding in stably transfected cells

    PMID:9169459

    Open questions at the time
    • Did not define downstream G-protein coupling
    • No structural basis for ligand recognition
    • Secondary β-defensin ligands not yet identified
  2. 2000 High

    Whether CCR6 had a non-redundant physiological role was unknown; knockout mice showed it is required for dendritic-cell positioning in the gut subepithelial dome and for mucosal humoral immunity.

    Evidence CCR6-knockout mouse immunohistochemistry and oral antigen/rotavirus challenge

    PMID:10843382 PMID:11254677

    Open questions at the time
    • Molecular signaling underlying DC positioning not defined
    • Did not address other CCR6+ cell types
    • Systemic vs mucosal compartmentalization mechanism unresolved
  3. 2000 High

    Defining which cell types use CCR6 mapped the breadth of its trafficking program; mature/memory B cells, neutrophils, and myeloid DC subsets were shown to be functionally CCR6-responsive and cytokine-regulated.

    Evidence Flow cytometry, transmigration assays, radioligand binding, CCR6-EGFP knock-in reporter, and cytokine stimulation across cell types

    PMID:11001880 PMID:11090084 PMID:11698430 PMID:11754009

    Open questions at the time
    • Reporter does not establish in vivo migratory function for each subset
    • Cytokine regulation mostly single-lab in vitro
    • Functional consequence of subset-specific expression varies by context
  4. 2004 High

    The receptor's signaling output was undefined; apical CCL20 stimulation of polarized epithelium showed Gαi coupling that inhibits cAMP and phosphorylates p130Cas.

    Evidence Polarized intestinal epithelial cell lines, pertussis toxin perturbation, cAMP/chloride secretion and p130Cas phosphorylation readouts

    PMID:15483227

    Open questions at the time
    • Did not link signaling to specific migratory or transcriptional outputs
    • Single epithelial-cell context
    • β-arrestin / desensitization arm not addressed
  5. 2008 High

    How CCR6 expression is wired to T-helper identity was unknown; TGF-β with RORα/RORγt was shown to drive CCR6 in Th17 cells, which also make CCL20, creating an autocrine recruitment loop tied to autoimmune disease.

    Evidence In vitro Th17 differentiation, nuclear receptor gain/loss, CCR6-deficient mice in EAE, migration assays

    PMID:19050256

    Open questions at the time
    • Direct transcription-factor binding at CCR6 locus not shown here
    • Th17 vs Treg balance not addressed
    • Human relevance inferred from mouse model
  6. 2010 Medium

    Whether CCR6 marks distinct regulatory T-cell function was open; CCR6 was shown to define colon-tropic IL-10+ iTregs whose suppressive capacity depends on the receptor.

    Evidence T-cell transfer colitis model with CCR6-KO and co-transfer experiments

    PMID:20720211

    Open questions at the time
    • Mechanism linking CCR6 to suppressive function not defined
    • Single disease model
    • Whether effect is migration-dependent or intrinsic unclear
  7. 2011 High

    Extending CCR6 trafficking beyond lymphocytes, monocyte homeostasis and pDC homing were shown to be CCR6-dependent, implicating the receptor in atherosclerosis and inflamed-tissue surveillance.

    Evidence Ccr6−/−ApoE−/− mice, bone marrow chimeras, monocyte chemotaxis, competitive pDC adoptive transfer in skin tumor model

    PMID:21680896 PMID:21937703

    Open questions at the time
    • Distinguishing monocyte mobilization from local chemotaxis requires further dissection
    • pDC findings single-lab
    • Downstream signaling in monocytes/pDCs not characterized
  8. 2013 High

    The role of CCR6 in tissue-specific inflammatory positioning was clarified across liver, eye, and vascular contexts, including a protective γδ T-cell axis driving HSC apoptosis via Fas-ligand.

    Evidence CCR6-KO mice in liver fibrosis and dry eye models, adoptive transfer epistasis, antibody blockade, monocyte adhesion assays

    PMID:23702781 PMID:23959575 PMID:24114205

    Open questions at the time
    • Cell-contact apoptosis mechanism downstream of recruitment, not receptor signaling
    • Some readouts antibody-blockade only
    • Context-dependent pro- vs anti-inflammatory roles unresolved
  9. 2015 High

    Direct transcriptional control of CCR6 was established; PLZF (ZBTB16) binds upstream enhancer elements and is required for CCR6 and Th17 gene expression, cross-regulating RORγt.

    Evidence ChIP for PLZF/p300/histone marks and ZBTB16 siRNA knockdown in human Th17 cells

    PMID:25833398

    Open questions at the time
    • Did not test CCR6 enhancer activity in reporter assays
    • Mechanism of PLZF-RORγt cross-regulation incomplete
    • Single-lab human T-cell system
  10. 2016 High

    CCR6 function beyond immune trafficking emerged; it drives osteoblast differentiation/survival via PI3K-AKT and promotes tumor angiogenesis through AKT/NF-κB/VEGF-A.

    Evidence Ccr6−/− and Ccl20−/− mice with µCT/histomorphometry, osteoblast differentiation and AKT assays, CRC cell knockdown/overexpression with HUVEC angiogenesis assays

    PMID:26890063 PMID:29097259

    Open questions at the time
    • Cell-intrinsic osteoblast vs immune-mediated bone effect not fully separated
    • Angiogenesis findings single-lab
    • Whether bone role uses canonical Gαi chemotaxis machinery unclear
  11. 2017 Medium

    How CCR6 signaling shapes Treg/Th17 plasticity was addressed; CCL20-CCR6 inhibits iTreg suppressor function and drives Treg-to-Th17 conversion via Akt/mTOR/STAT3.

    Evidence In vitro Treg differentiation/suppression assays with CCR6 blockade and phospho-western blots

    PMID:29126851

    Open questions at the time
    • In vitro only
    • In vivo relevance of lineage conversion not shown here
    • STAT3/mTOR causality not tested by pathway inhibition
  12. 2017 Medium

    A non-canonical CCR6 role in sperm was defined; CCR6 physically interacts with CatSper to mediate ligand-induced Ca2+ influx required for motility, hyperactivation, and acrosome reaction.

    Evidence Co-IP, co-localization, siRNA knockdown, Ca2+ current and sperm functional assays in human sperm

    PMID:23765988 PMID:29207656

    Open questions at the time
    • Stoichiometry/structural basis of CCR6-CatSper interaction unknown
    • Single Co-IP without reciprocal structural validation
    • Whether Gαi signaling participates unclear
  13. 2018 Low

    Whether CCR6 itself is somatically altered in cancer was tested; truncating mutations cluster in the C-terminal tail in MALT lymphoma, predicted to abolish β-arrestin-mediated desensitization.

    Evidence Whole exome sequencing of MALT lymphoma with bioinformatic clustering analysis

    PMID:29674500

    Open questions at the time
    • Functional consequence inferred but not experimentally validated
    • Constitutive signaling not demonstrated
    • No β-arrestin recruitment assay performed
  14. 2020 High

    The structural basis of CCR6 activation was resolved; cryo-EM showed CCL20 binds a shallow extracellular pocket and allosterically opens the G-protein crevice without deep 7-TM engagement.

    Evidence 3.3 Å cryo-EM of CCL20–CCR6–engineered Gαo complex

    PMID:32541785

    Open questions at the time
    • β-defensin secondary-ligand binding mode not resolved
    • Dynamics of toggle-switch rearrangement static-structure inferred
    • Did not capture inactive/antagonist states
  15. 2022 High

    CCR6 was placed downstream of epithelial tumor-suppressor loss and as an amplifier of inflammatory cross-talk; deleting Ccr6 abrogated immune recruitment in SMAD4-loss carcinogenesis and broke an IL-6/CCL20 dermatitis loop.

    Evidence Conditional Smad4-KO × Ccr6-KO epistasis with tumor quantification, and Ccr6/IL-6 KO crosses with scRNA-seq in radiation dermatitis

    PMID:35785521 PMID:35863523

    Open questions at the time
    • Which CCR6+ cell type is the dominant effector not fully resolved
    • Cross-talk loop mechanism partly correlative
    • Translation to human disease inferred
  16. 2022 Medium

    A receptor-scaffold mechanism beyond chemotaxis was found; CCR6 binds TFEB and blocks its nuclear translocation, inhibiting autophagic flux to promote endometriotic stromal cell proliferation.

    Evidence Co-IP of CCR6/TFEB, TFEB translocation and mRFP-GFP-LC3 autophagic flux assays, CCL20-neutralizing antibody mouse model

    PMID:35841069

    Open questions at the time
    • Direct vs indirect CCR6-TFEB binding not distinguished
    • Single Co-IP context
    • Relationship to canonical Gαi signaling unknown
  17. 2024 High

    The inactive-state pharmacology and metabolic immunosuppressive role were defined; two allosteric antagonist pockets were structurally mapped, and CCR6 was shown to drive Treg glycolysis required for CD8 suppression and immunotherapy resistance.

    Evidence Cryo-EM of inactive CCR6 with OXM and SQA1 antagonists; Ccr6-KO mice in multiple tumor models with metabolic and anti-PD-1 assays; antagonist binding-kinetics studies

    PMID:37142443 PMID:39133127 PMID:39217154

    Open questions at the time
    • Minimal cooperativity between pockets limits dual-targeting strategy clarity
    • Metabolic mechanism single-lab
    • Antagonist efficacy in human disease not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • How CCR6's diverse non-chemotactic functions (osteoblast survival, CatSper coupling, TFEB sequestration) mechanistically relate to its canonical Gαi-chemotaxis machinery, and whether they share or diverge from the structurally defined activation network, remains unresolved.
  • No unified signaling model linking scaffold and chemotactic roles
  • β-arrestin/desensitization regulation not experimentally characterized in disease mutants
  • Cell-type-specific effector wiring undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3 GO:0098772 molecular function regulator activity 2 GO:0048018 receptor ligand activity 1
Localization
GO:0005886 plasma membrane 4
Pathway
R-HSA-168256 Immune System 4 R-HSA-1500931 Cell-Cell communication 3 R-HSA-162582 Signal Transduction 3
Partners
CATSPER1CCL20CRKLTFEB

Evidence

Reading pass · 38 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 CCR6 (then called GPR-CY4) is the specific receptor for the chemokine LARC/CCL20: LARC induced calcium flux and migration in cells stably expressing GPR-CY4, and LARC-SEAP fusion protein bound specifically to GPR-CY4-expressing cells with a Kd of 0.9 nM. No other tested CC chemokines (MCP-1, RANTES, MIP-1α, MIP-1β, TARC) competed for this binding. Calcium mobilization assay, chemotaxis assay, ligand-binding assay with SEAP-fusion protein in stably transfected cells The Journal of biological chemistry High 9169459
2000 CCR6 is required for dendritic cell localization to the subepithelial dome of Peyer's patches and for normal mucosal humoral immune responses; CCR6-knockout mice lack CD11c+CD11b+ DCs in the subepithelial dome, have impaired IgA responses to oral antigens/rotavirus, and show 2–15-fold increases in intestinal T-cell subpopulations, while systemic responses remain normal. CCR6 knockout mouse analysis, immunohistochemistry, immune challenge with oral antigen and rotavirus Immunity High 10843382
2001 CCR6 deficiency results in underdeveloped Peyer's patches lacking myeloid CD11b+CD11c+ DCs in the subepithelial dome, increased intestinal T-cell numbers, exaggerated contact hypersensitivity responses, and absent delayed-type hypersensitivity responses, demonstrating CCR6 is required for proper DC and T-cell trafficking in cutaneous and intestinal immunity. CCR6 knockout mouse model, histology, CHS and DTH assays The Journal of clinical investigation High 11254677
2000 CCR6 expression on B cells is acquired upon maturation into naive/memory B cells and is absent from germinal center B cells and plasma cells; CCL20/MIP-3α induces vigorous B-cell transmigration with preferential chemotaxis of IgD− memory B cells, establishing functional CCR6-dependent chemotaxis in B-cell subsets. Flow cytometry, transmigration chemotaxis assays across defined B-cell differentiation stages Blood Medium 11001880
2000 TNF-α induces CCR6 expression on cytokine-activated neutrophils, rendering them functionally responsive to its ligand LARC/CCL20 (demonstrated by 125I-LARC binding and dose-dependent migration); IFN-γ induces lower CCR6 levels and the two cytokines act synergistically. Northern blot, 125I-labeled LARC binding assay, chemotaxis assay, neutralizing antibody experiments Blood Medium 11090084
2002 CCR6 is expressed predominantly on myeloid (CD11b+) but not lymphoid (CD8α+) dendritic cell subsets, on all mature B cells, and on subsets of T cells, as demonstrated by a CCR6-EGFP knock-in reporter mouse; CD4+ myeloid DCs are uniformly CCR6+, and Langerhans cells express CCR6 at lower levels. CCR6-EGFP knock-in mouse, flow cytometry, bone marrow culture European journal of immunology High 11754009
2001 IL-10 maintains CCR6 expression during Langerhans cell development and induces CCR6 on monocytes, while IL-4 transiently suppresses CCR6 (reversible blockade of LC differentiation) and IFN-γ irreversibly downregulates CCR6 coincident with DC maturation; TGF-β triggers irreversible CCR6 downregulation during terminal LC differentiation. In vitro cytokine stimulation of DC precursors, flow cytometry, functional CCL20 responsiveness assays Journal of immunology Medium 11698430
2004 CCR6 expressed on polarized intestinal epithelial cells (predominantly apically) signals via Gαi proteins upon apical CCL20 stimulation: it induces tyrosine phosphorylation of p130Cas (Crk-associated substrate) and inhibits cAMP production and cAMP-mediated chloride secretion; pertussis toxin abolishes cAMP inhibition, confirming Gαi coupling. Polarized T84/Caco-2/HT-29/HCA-7 cell lines, apical stimulation with CCL20, pertussis toxin inhibition, p130Cas phosphorylation assay, cAMP/chloride secretion measurements American journal of physiology. Cell physiology High 15483227
2005 CCR6 on donor CD4+ T cells is required for their migration to and infiltration of target tissues (skin, gut) in graft-versus-host disease; CCR6-deficient donors showed reduced skin/gut CD4+ infiltration, delayed lesion onset, milder pathology, and lower IFN-γ, IL-10, and homing-chemokine levels in target organs. Allogeneic GvHD mouse models (MHC class II-mismatched and MHC-matched/miHA-mismatched), CCR6-knockout donors, histopathology, cytokine measurement Blood Medium 15774622
2008 CCR6 expression in Th17 cells is regulated by TGF-β and requires the nuclear receptors RORα and RORγ; Th17 cells also produce the CCR6 ligand CCL20 (induced synergistically by TGF-β and IL-6 via STAT3, RORγ, and IL-21), enabling autocrine/paracrine CCR6-dependent recruitment. CCR6-deficient Th17 cells show reduced recruitment into EAE inflammatory tissues and reduced disease severity. In vitro differentiation of Th17 cells, nuclear receptor overexpression/knockout, CCR6-deficient mice in EAE model, in vitro migration assays Journal of immunology High 19050256
2009 CCR6 ligands (CCL20 and β-defensins) induce expression of the HIV restriction factor APOBEC3G in CCR6+ CD4+ T cells through a Gαi-dependent pathway (blocked by pertussis toxin), providing a post-entry mechanism of HIV inhibition in CCR6+ cells. APOBEC3G induction assay in CCR6+ vs. CCR6− cells, pertussis toxin inhibition, HIV infection assays Blood Medium 20023216
2010 CCR6 on regulatory T cells marks colon-tropic, IL-10-producing iTregs; CCR6-deficient iTregs have impaired suppressive capacity in a T-cell transfer colitis model despite equivalent frequency in lymph nodes and colon, and CCR6+ Tregs preferentially migrate to the inflamed colon. Rag2−/− T-cell transfer colitis model, CCR6-KO mice, cotransfer experiments, flow cytometry, cytokine measurements Journal of immunology Medium 20720211
2011 CCR6 on plasmacytoid dendritic cells (pDCs) is acquired after IL-3-driven instruction in lymphoid tissues (following initial CCR7 upregulation), enabling CCR6-dependent homing of pDCs to inflamed epithelia; competitive adoptive transfer in CCR6-deficient mice confirmed that CCR6 is required for pDC homing to inflamed skin tumors. Competitive adoptive transfer of WT vs. CCR6-deficient pDCs, imiquimod skin tumor model, IL-3 culture induction, flow cytometry Blood Medium 21937703
2011 CCR6 promotes atherogenesis by supporting monocyte homeostasis in blood and direct CCL20-induced monocyte chemotaxis: Ccr6−/−ApoE−/− mice have ~40% less aortic lesion area with 44% less macrophage content; CCL20 induces chemotaxis of WT but not Ccr6−/− primary monocytes; bone marrow transplant from Ccr6−/− donors into ApoE−/− mice recapitulates the atheroprotection. Ccr6−/−ApoE−/− double-KO mice, bone marrow transplantation, in vitro monocyte chemotaxis assay, CCL20 injection in vivo (monocytosis assay), lesion quantification Circulation research High 21680896
2012 CCR6 mediates positioning of Th17 cells near bile ducts in the inflamed liver: cholangiocytes stimulated by cytokines secrete CCL20, which induces CCR6-dependent migration of Th17 cells; CCR6 blockade in vitro reduces Th17 migration toward cholangiocyte-conditioned medium. In vitro chemotaxis assay with CCR6-blocking antibody, CXCR3 antibody blockade in vivo (intravital microscopy), flow cytometry of liver-infiltrating cells Journal of hepatology Medium 22796894
2013 CCR6 is required for accumulation of IL-17/IL-22-expressing γδ T cells in injured liver; Ccr6−/− mice develop more severe fibrosis with enhanced immune infiltration in chronic liver injury models (CCl4 and MCD diet); adoptive transfer of WT (but not CD4) γδ T cells into Ccr6−/− mice reduces hepatic inflammation and fibrosis to WT levels; hepatic γδ T cells promote HSC apoptosis via Fas-ligand in a cell-contact-dependent, IL-17-independent manner. Ccr6−/− mice in chronic liver injury models, adoptive transfer of γδ vs. CD4 T cells, flow cytometry, in vitro HSC apoptosis assay, Il-17−/− cell transfer Hepatology High 23959575
2013 CCR6 on Th17 cells mediates migration to the ocular surface in dry eye disease via CCL20 expressed by the conjunctival epithelium; subconjunctival neutralization of CCL20 reduces in vitro T-cell migration and decreases conjunctival Th17 infiltration and inflammatory cytokines in vivo. CCR6-KO mice, dry eye disease model, in vitro chemotaxis assay with CCL20-neutralizing antibody, subconjunctival antibody administration in vivo, flow cytometry Investigative ophthalmology & visual science Medium 23702781
2014 CCR6 in mouse sperm is localized predominantly to the sperm tail and is functional: human sperm exhibit directional chemotaxis and motility changes toward CCL20 in vitro, and CCR6 ligands (including CCL20 and DEFB29) are present in reproductive tract fluids. Immunofluorescence and immunoblot for CCR6 in mouse and human sperm, RT-PCR for Ccr6/Defb29 mRNA in testis/epididymis, protein chip analysis of reproductive fluids, in vitro sperm chemotaxis assay Journal of cellular physiology Medium 23765988
2014 CCL20-CCR6 interactions promote spontaneous intestinal tumorigenesis: CCR6KO-ApcMin/+ mice have diminished tumor number and normalized spleen size compared to ApcMin/+ mice; CCR6 loss reduces macrophage infiltration into adenomas; CCL20 signaling through CCR6 increases CCL20 production by colorectal cancer cells (autocrine loop) and has a direct mitogenic effect on cancer cells. CCR6-KO × ApcMin/+ mouse cross, tumor quantification, macrophage infiltration immunostaining, CCL20 stimulation of cancer cell lines PloS one Medium 24866282
2015 PLZF (encoded by ZBTB16) is a transcriptional activator that regulates CCR6 expression in human Th17 cells: PLZF binds enhancer-like sites at −9/−10 and −13/−14 kb upstream of the CCR6 transcription start site (by ChIP), and ZBTB16 knockdown downregulates CCR6 and other Th17 genes; PLZF and RORγt cross-regulate each other, and PLZF binds at the RORC promoter in CCR6+ cells. ChIP for modified histones, p300, and PLZF; siRNA knockdown of ZBTB16 in human T cells; transcriptome analysis; CCR6 expression monitoring Journal of immunology High 25833398
2016 CCR6 on B cells negatively regulates germinal center entry: CCR6-deficient mice show accelerated GC appearance, increased dark zone/light zone ratio, decreased antigen-specific IgG1 and IgG2a (but not IgM) in a B-cell-intrinsic manner in mixed bone marrow chimeras; CCR6 is rapidly upregulated on activated B cells and only activated B cells migrate toward CCL20. Mixed bone marrow chimeras (WT vs. CCR6-KO), flow cytometry for GC kinetics and DZ/LZ ratio, ELISA for antigen-specific antibodies, in vitro CCL20 migration assay Immunology and cell biology Medium 27465674
2017 CCR6 signaling inhibits iTreg suppressor function and directs Treg-to-Th17 lineage conversion: CCL20 inhibits TGF-β1-induced iTreg differentiation in a CCR6-dependent manner, reduces surface expression of suppressor molecules (CD39, CD73, FasL), impairs suppressive function, and induces phosphorylation of Akt, mTOR, and STAT3. In vitro Treg differentiation assays with/without CCL20 and CCR6 blockade, flow cytometry for Treg markers, phospho-western blots for Akt/mTOR/STAT3, suppression assays Journal of autoimmunity Medium 29126851
2017 CCR6 is required for ligand-induced CatSper-dependent Ca2+ influx in human sperm: CCR6 co-localizes and co-immunoprecipitates with CatSper; siRNA knockdown of either CCR6 or CatSper abolishes Ca2+ influx induced by DEFB1, CCL20, and progesterone; this Ca2+ pathway is required for sperm motility, hyperactivation, and acrosome reaction, which are impaired in infertile sperm with reduced CCR6/CatSper levels. Co-immunoprecipitation, co-localization by immunofluorescence, siRNA knockdown, Ca2+ current measurements, sperm functional assays (motility, hyperactivation, acrosome reaction) Oncotarget Medium 29207656
2018 Somatic truncating mutations (nonsense and frameshift) in CCR6 cluster in the C-terminal cytoplasmic tail in MALT lymphomas; these mutations are predicted to remove the phosphorylation motif required for β-arrestin-mediated receptor desensitization and internalization, suggesting gain-of-constitutive signaling. Whole exome sequencing of MALT lymphoma samples, bioinformatic analysis of mutation clustering Haematologica Low 29674500
2020 Cryo-EM structure of human CCR6 bound to its endogenous ligand CCL20 and an engineered Gαo protein at 3.3 Å resolution shows CCL20 binds in a shallow extracellular pocket making limited contact with the 7-TM core; this binding allosterically rearranges a noncanonical toggle switch and opens the intracellular crevice for G protein coupling, demonstrating that protein-agonist GPCR activation does not always require deep 7-TM interactions. Cryo-electron microscopy structure determination at 3.3 Å, structural analysis of activation mechanism Nature communications High 32541785
2016 CCL20/CCR6 promotes tumor angiogenesis in colorectal cancer via the AKT/NF-κB/VEGF-A pathway: CCR6 silencing decreases HUVEC proliferation and migration, while CCR6 overexpression promotes angiogenesis; mechanistically, CCR6 activation leads to AKT/NF-κB pathway activation and increased VEGF-A secretion. CCR6 siRNA knockdown and overexpression in CRC cells, HUVEC proliferation and migration assays, AKT/NF-κB signaling analysis, in vivo angiogenesis assay Biochimica et biophysica acta. Molecular basis of disease Medium 29097259
2016 CCL20/CCR6 signaling regulates bone mass accrual: Ccr6−/− mice have significantly decreased trabecular bone mass with reduced osteoblast numbers; CCL20 and CCR6 are co-expressed in osteoblast progenitors and upregulated during differentiation; CCR6 acts as a functional Gprotein-coupled receptor in osteoblasts; CCR6 loss inhibits osteoblast differentiation (markers, alkaline phosphatase, mineralization); CCL20 promotes osteoblast survival via PI3K-AKT; Ccl20−/− mice recapitulate the bone loss phenotype confirming specificity. μCT and histomorphometry in Ccr6−/− and Ccl20−/− mice, osteoblast differentiation assays, AKT phosphorylation assays, macrophage/T-cell recruitment assays Journal of bone and mineral research High 26890063
2019 Cisplatin-stimulated macrophages promote ovarian cancer cell migration via CCL20 secretion activating CCR6 on cancer cells, triggering epithelial-to-mesenchymal transition; pharmacological CCL20 blockade on macrophages and siRNA-mediated CCR6 silencing in cancer cells abrogated migration induced by cisplatin-stimulated macrophages. Macrophage-cancer cell co-culture, cisplatin stimulation, CCL20 ELISA, siRNA CCR6 knockdown, migration assays, EMT marker analysis Cancer letters Medium 31866467
2017 In CTCL, STAT3 is spontaneously activated and transcribes CCL20; CCL20 then signals through CCR6 in an autocrine manner to drive migration; knockdown of STAT3, CCL20, or CCR6, or CCL20 neutralizing antibody, all reduce CTCL cell migration in vitro; CCL20-neutralizing antibody prolongs survival of CTCL xenograft mice. STAT3/CCL20/CCR6 siRNA knockdown, CCL20 neutralizing antibody, in vitro migration assay, NOD/SCID xenograft mouse survival Oncotarget Medium 26789110
2022 SMAD4 loss in colon epithelium increases CCL20 expression and chemoattracts CCR6+ immune cells (T regulatory, Th17, dendritic cells), promoting colitis-associated carcinogenesis; genetic deletion of Ccr6 abrogated these immune responses and significantly reduced tumor incidence in Smad4-conditional KO mice. Conditional colon-epithelial Smad4 KO mice with/without germline Ccr6 deletion, colitis model, tumor quantification, flow cytometry, immunostaining Gastroenterology High 35863523
2024 Two inactive CCR6 structures determined by cryo-EM reveal two allosteric antagonist binding pockets: an extracellular pocket occupied by oxomorpholine antagonists (OXM1/OXM2) that disrupt the receptor activation network, and an intracellular pocket occupied by squaramide SQA1 that overlaps with the G protein binding site, stabilizing a closed (inactive) conformation; minimal allosteric cooperativity between the two pockets was observed. Cryo-EM structural determination of two ternary CCR6/SQA1/OXM complexes, pharmacological characterization of antagonist binding Nature communications High 39217154
2024 CCR6-CCL20 signaling in tumor-infiltrating Tregs promotes glycolysis and lactate production, which is required for their immunosuppressive activity toward CD8+ T cells; Ccr6−/− Tregs show reduced glycolysis and lactic acid production with compensatory glutamine metabolism; Ccr6−/− mice show improved survival across multiple tumor models and enhanced anti-PD-1 efficacy in glioma. Ccr6-KO mice in multiple tumor models, metabolic assays (glycolysis, lactate, glutamine), CD8 T-cell suppression assays, anti-PD-1 combination therapy, CCL20 siRNA knockdown Cancer immunology research Medium 39133127
2022 CCR6 deficiency in CCR6−/− mice strongly ameliorates radiation-induced alopecia and dermatitis (IRIAD); IL-6 deficiency reduces CCL20 and CCR6 upregulation, while CCR6 deficiency reciprocally reduces IL-6, IL-17, CCL3, and MHC upregulation, revealing a proximity-dependent cellular cross-talk loop amplifying radiation dermatitis. CCR6−/− mice, IL-6−/− mice, IL-1R−/− mice, scRNA-seq, genetic ablation studies, molecular inhibitor studies (JAK blockers, cyclosporine) EMBO molecular medicine Medium 35785521
2015 CrkL adapter protein mediates CCL20/CCR6-induced epithelial-to-mesenchymal transition in gastric cancer via the Akt pathway (not ERK1/2): CCL20 activates p-CrkL, p-ERK1/2, p-Akt, vimentin, N-cadherin and MMP2 in a dose-dependent manner; si-CrkL ablates CCL20-induced vimentin, N-cadherin, MMP2 and migration/invasion, but does not affect p-ERK1/2. siRNA knockdown of CrkL, CCL20 stimulation dose-response, western blot for signaling pathway components, migration/invasion assays Cytokine Medium 26044596
2009 CCL20/MIP-3α accounts for ~40% of RA synovial fluid chemotactic activity for monocytes; in vitro monocyte chemotaxis induced by MIP-3α is inhibited by pertussis toxin pretreatment of monocytes, confirming signaling through a Gi-coupled receptor. Modified Boyden chamber monocyte chemotaxis assay, pertussis toxin inhibition, ELISA, flow cytometry Laboratory investigation Medium 12695561
2013 CCR6 selectively promotes monocyte (but not T cell) adhesion to inflamed endothelium and monocyte recruitment in an acute air-pouch inflammatory model; CCR6 reduces circulating Gr-1high and Gr-1low monocytes in Ccr6−/−Ldlr−/− mice, establishing a role for CCR6 in monocyte mobilization, adhesion, and chemotaxis that drives atherosclerosis. Ccr6−/−Ldlr−/− double-KO mice, in vitro monocyte adhesion assay to inflamed endothelium, in vivo air pouch monocyte recruitment model, flow cytometry Thrombosis and haemostasis Medium 24114205
2023 PF-07054894 is a CCR6 antagonist that binds with slow dissociation kinetics (slower off-rate for CCR6 vs. CCR7/CXCR2) producing insurmountable inhibition of CCL20/CCR6-mediated human T-cell chemotaxis; oral administration in cynomolgus monkeys increases circulating CCR6+ T cells (consistent with blockade of homeostatic tissue egress); the compound also causes upregulation of cell-surface CCR6 in B cells in vivo and in vitro. β-arrestin GPCR panel screen (168 receptors), human T-cell chemotaxis assay, [3H]-PF-07054894 radioligand binding/dissociation kinetics, in vivo primate pharmacology, IL-23 mouse skin model The Journal of pharmacology and experimental therapeutics Medium 37142443
2022 CCR6 in endometriosis: CCR6 binds TFEB in ESCs (co-IP confirmed), inhibiting TFEB nuclear translocation, thereby blocking lysosomal function and autophagic flux (autolysosome degradation), which promotes ESC proliferation and migration; macrophage-derived CCL20 activates this CCR6-TFEB pathway in co-culture. Co-immunoprecipitation (CCR6/TFEB), TFEB nuclear translocation assay, mRFP-GFP-LC3 autophagic flux reporter, lysosome function assays (Lyso-tracker, Gal3, acid phosphatase), CCL20-neutralizing antibody in vivo mouse model Stem cell research & therapy Medium 35841069

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 The CC chemokine CCL20 and its receptor CCR6. Cytokine & growth factor reviews 665 12948524
2008 CCR6 regulates the migration of inflammatory and regulatory T cells. Journal of immunology (Baltimore, Md. : 1950) 443 19050256
2000 CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 384 10843382
1997 Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. The Journal of biological chemistry 353 9169459
2020 CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. International journal of molecular sciences 308 33076281
2009 Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. Journal of immunology (Baltimore, Md. : 1950) 274 20042588
2004 CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 241 15613550
2009 CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells. European journal of immunology 236 19830744
2020 The CCL20-CCR6 Axis in Cancer Progression. International journal of molecular sciences 214 32707869
2011 CCR6 as a mediator of immunity in the lung and gut. Experimental cell research 196 21376174
2021 CCR6-CCL20 axis as a therapeutic target for autoimmune diseases. Autoimmunity reviews 184 33971346
2012 CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. Journal of hepatology 174 22796894
2013 Chemokine receptor CCR6-dependent accumulation of γδ T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology (Baltimore, Md.) 169 23959575
2001 CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses. The Journal of clinical investigation 169 11254677
2000 Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory protein-3alpha/CCL20 in human B cells. Blood 142 11001880
2006 CCR6 and CCL20: partners in intestinal immunity and lymphorganogenesis. Annals of the New York Academy of Sciences 137 17057190
2017 HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. AIDS (London, England) 126 27835617
2009 The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. International journal of cancer 120 19480006
2000 Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 115 11090084
2015 The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. Cytokine 111 25828206
2003 Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Laboratory investigation; a journal of technical methods and pathology 110 12695561
2010 An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation?: CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. BioEssays : news and reviews in molecular, cellular and developmental biology 101 20954179
2019 Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis. Cancer letters 89 31866467
2020 Structural basis for chemokine receptor CCR6 activation by the endogenous protein ligand CCL20. Nature communications 85 32541785
2022 CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling. Molecular cancer 83 36045408
2006 Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 78 16641550
2002 CCR6 expression distinguishes mouse myeloid and lymphoid dendritic cell subsets: demonstration using a CCR6 EGFP knock-in mouse. European journal of immunology 78 11754009
2020 Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment. JCI insight 76 32554933
2019 The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology. Immunobiology 74 30772094
2010 CCR6 marks regulatory T cells as a colon-tropic, IL-10-producing phenotype. Journal of immunology (Baltimore, Md. : 1950) 72 20720211
2005 CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood 72 15774622
2013 The CCR6/CCL20 axis mediates Th17 cell migration to the ocular surface in dry eye disease. Investigative ophthalmology & visual science 66 23702781
2016 Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview. World journal of gastroenterology 65 26811629
2024 Lipid droplet accumulation mediates macrophage survival and Treg recruitment via the CCL20/CCR6 axis in human hepatocellular carcinoma. Cellular & molecular immunology 64 38942796
2011 Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PloS one 64 21949768
2018 Modulation of the CCR6-CCL20 Axis: A Potential Therapeutic Target in Inflammation and Cancer. Medicina (Kaunas, Lithuania) 62 30453514
2014 A role for the chemokine receptor CCR6 in mammalian sperm motility and chemotaxis. Journal of cellular physiology 58 23765988
2017 CCR6 promotes tumor angiogenesis via the AKT/NF-κB/VEGF pathway in colorectal cancer. Biochimica et biophysica acta. Molecular basis of disease 57 29097259
2003 Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood 57 12642342
2017 CCR6 signaling inhibits suppressor function of induced-Treg during gut inflammation. Journal of autoimmunity 55 29126851
2018 Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites. Haematologica 53 29674500
2007 Functional expression of chemokine receptor CCR6 on human effector memory CD8+ T cells. European journal of immunology 53 17171755
2015 Identification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach. Retrovirology 52 26654242
2015 CrkL meditates CCL20/CCR6-induced EMT in gastric cancer. Cytokine 50 26044596
2014 CCR6 and CCL20: emerging players in the pathogenesis of rheumatoid arthritis. Immunology and cell biology 50 24394994
2010 CCR6 as a possible therapeutic target in psoriasis. Expert opinion on therapeutic targets 50 20629596
2014 CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis. PloS one 48 24866282
2011 Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice. Circulation research 48 21680896
2007 Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. Journal of leukocyte biology 47 17615381
2020 Human Immunodeficiency Virus (HIV)-Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. The Journal of infectious diseases 46 31796951
2016 CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. British journal of cancer 45 27149649
2011 CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. Blood 45 21937703
2022 SMAD4 Suppresses Colitis-associated Carcinoma Through Inhibition of CCL20/CCR6-mediated Inflammation. Gastroenterology 43 35863523
2015 CCR6(+) Th cell populations distinguish ACPA positive from ACPA negative rheumatoid arthritis. Arthritis research & therapy 43 26617177
2009 CCR6 ligands inhibit HIV by inducing APOBEC3G. Blood 43 20023216
2017 Role of CCL20/CCR6 and the ERK signaling pathway in lung adenocarcinoma. Oncology letters 41 29250193
2017 Enrichment of Human CCR6+ Regulatory T Cells with Superior Suppressive Activity in Oral Cancer. Journal of immunology (Baltimore, Md. : 1950) 40 28600287
2022 Single-cell transcriptomics reveals a senescence-associated IL-6/CCR6 axis driving radiodermatitis. EMBO molecular medicine 38 35785521
2018 Expression of CCR6 and CXCR6 by Gut-Derived CD4+/CD8α+ T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases. Gastroenterology 38 29981781
2015 The relationship between CCR6 and its binding partners: does the CCR6-CCL20 axis have to be extended? Cytokine 37 25585877
2022 Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy. Cancer immunology, immunotherapy : CII 36 36326893
2021 Single-cell sequencing unveils distinct immune microenvironments with CCR6-CCL20 crosstalk in human chronic pancreatitis. Gut 36 34702715
2015 PLZF regulates CCR6 and is critical for the acquisition and maintenance of the Th17 phenotype in human cells. Journal of immunology (Baltimore, Md. : 1950) 36 25833398
2010 Chicken CCR6 and CCR7 are markers for immature and mature dendritic cells respectively. Developmental and comparative immunology 36 21195108
2004 Chemokine receptor CCR6 transduces signals that activate p130Cas and alter cAMP-stimulated ion transport in human intestinal epithelial cells. American journal of physiology. Cell physiology 36 15483227
2016 Early CCR6 expression on B cells modulates germinal centre kinetics and efficient antibody responses. Immunology and cell biology 35 27465674
2001 IL-10 induces CCR6 expression during Langerhans cell development while IL-4 and IFN-gamma suppress it. Journal of immunology (Baltimore, Md. : 1950) 35 11698430
2017 CCR6/CCL20 chemokine axis in human immunodeficiency virus immunity and pathogenesis. The Journal of general virology 34 28005525
2019 CCL20-CCR6 axis modulated traumatic brain injury-induced visual pathologies. Journal of neuroinflammation 33 31151410
2016 CCL20/CCR6 promotes cell proliferation and metastasis in laryngeal cancer by activating p38 pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 32 27916417
2012 Investigation of JAK2, STAT3 and CCR6 polymorphisms and their gene-gene interactions in inflammatory bowel disease. International journal of immunogenetics 32 22269120
2023 CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases. Antibodies (Basel, Switzerland) 31 37092451
2019 DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway. Oncology reports 31 31322256
2020 Keratinocyte transglutaminase 2 promotes CCR6+ γδT-cell recruitment by upregulating CCL20 in psoriatic inflammation. Cell death & disease 27 32355189
2019 Differential expression of CXCR3 and CCR6 on CD4+ T-lymphocytes with distinct memory phenotypes characterizes tuberculosis-associated immune reconstitution inflammatory syndrome. Scientific reports 26 30728405
2016 Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma. Oncotarget 26 26789110
2013 CCR6 selectively promotes monocyte mediated inflammation and atherogenesis in mice. Thrombosis and haemostasis 26 24114205
2010 Expression of the chemokine receptor CCR6 in human renal inflammation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 26 20844183
2021 Reduced CCR6+IL-17A+Treg Cells in Blood and CCR6-Dependent Accumulation of IL-17A+Treg Cells in Lungs of Patients With Allergic Asthma. Frontiers in immunology 25 34497608
2020 Cigarette smoking induces human CCR6+Th17 lymphocytes senescence and VEGF-A secretion. Scientific reports 25 32300208
2010 Expression of chemokine receptor CCR6 as a molecular determinant of adrenal metastatic relapse in patients with primary lung cancer. Clinical lung cancer 25 20439195
2017 The loss of CCR6+ and CD161+ CD4+ T-cell homeostasis contributes to disease progression in SIV-infected rhesus macaques. Mucosal immunology 24 28051083
2016 Impairment of CCR6+ and CXCR3+ Th Cell Migration in HIV-1 Infection Is Rescued by Modulating Actin Polymerization. Journal of immunology (Baltimore, Md. : 1950) 24 27895171
2013 High CCR6/CCR7 expression and Foxp3+ Treg cell number are positively related to the progression of laryngeal squamous cell carcinoma. Oncology reports 24 23835793
2021 Targeting the CCR6/CCL20 Axis in Entheseal and Cutaneous Inflammation. Arthritis & rheumatology (Hoboken, N.J.) 23 34081845
2016 CCL20/CCR6 Signaling Regulates Bone Mass Accrual in Mice. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 23 26890063
2015 The abnormal expression of CCR4 and CCR6 on Tregs in rheumatoid arthritis. International journal of clinical and experimental medicine 23 26628988
2002 CCR6 is a functional chemokine receptor that serves to identify select B-cell non-Hodgkin's lymphomas. Human pathology 22 12514792
2024 RANKL/RANK signaling recruits Tregs via the CCL20-CCR6 pathway and promotes stemness and metastasis in colorectal cancer. Cell death & disease 21 38902257
2024 Structural basis for CCR6 modulation by allosteric antagonists. Nature communications 20 39217154
2023 PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20 37572185
2020 Treatment with shCCL20-CCR6 nanodendriplexes and human mesenchymal stem cell therapy improves pathology in mice with repeated traumatic brain injury. Nanomedicine : nanotechnology, biology, and medicine 20 32599163
2017 CCR6 is required for ligand-induced CatSper activation in human sperm. Oncotarget 20 29207656
2009 CCL20/CCR6 chemokine/receptor expression in bone tissue from osteoarthritis and rheumatoid arthritis patients: different response of osteoblasts in the two groups. Journal of cellular physiology 20 19492413
2020 The Role of CCL20-CCR6 Axis in Ovarian Cancer Metastasis. OncoTargets and therapy 19 33335408
2024 The CCR6-CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors. Cancer immunology research 18 39133127
2023 A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6+ T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation. The Journal of pharmacology and experimental therapeutics 18 37142443
2022 CCL20/CCR6 axis mediates macrophages to promote proliferation and migration of ESCs by blocking autophagic flux in endometriosis. Stem cell research & therapy 18 35841069
2021 CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature. EBioMedicine 18 34902786
2014 Chemokine receptor CCR6 expression is regulated by miR-518a-5p in colorectal cancer cells. Journal of translational medicine 18 24559209

Missed literature

Know a paper Affinage missed for CCR6? Flag it for the maintainers and the community.

No submissions yet.